GeneCentric Therapeutics Presents First Data on Novel Response Signatures to Treatment in Muscle Invasive Bladder Cancer (MIBC) Patients
GeneCentric Therapeutics will present the first data on novel response signatures for metastatic, muscle invasive bladder cancer (MIBC) treatments by applying its proprietary, RNA-sequencing based predictive response signature and Cancer Subtyping Platform (CSP).
GeneCentric Therapeutics will present the first data on novel response
signatures for metastatic, muscle invasive bladder cancer (MIBC)
treatments by applying its proprietary, RNA-sequencing based predictive
response signature and Cancer Subtyping Platform (CSP®). The initial
response signature and MIBC cohort data are being presented at a poster
session at the annual meeting of the American Society of Clinical
Oncology (ASCO) in Chicago, IL, later today.
“MIBC remains a significant area of unmet need for patients, with a
median 5-year survival rate of 5 percent,” said Dr. Mike Milburn,
CEO/President of GeneCentric and senior author on the study. “The advent
of immune checkpoint inhibitors (ICP) offers further treatment options
in MIBC, however, their clinical benefit varies considerably by patient.
We are excited to be at the forefront of advancing such gene response
signatures for the benefit of patients.”
The overall goal of the study, conducted by GeneCentric scientists in
collaboration with researchers at the University of North Carolina
Chapel Hill’s Lineberger Cancer Center, is to assess the genomic
characteristics of MIBC patients treated with ICPs and to assess the
potential implications of those characteristics on treatment responses
and outcomes. The study involves applying the Company’s 60-gene 4-class
MIBC expression subtyper (BCSP™) and an initial FGFR3 activation
response signature, developed from MIBC TCGA (The Cancer Genome Atlas)
data along with other proprietary assays, to a cohort of de-identified
MIBC patients who underwent prior ICP. To stratify and identify positive
or negative ICP response indicators, comprehensive genomic analyses were
performed on archived FFPE samples from patients within this cohort,
followed by tumor and immune profiling as well as subtype and other
response associated predictor analyses. The full analysis of the
complete dataset (n=97) will be presented at a future meeting.
Details of the presentation are as follows:
|
Title: “RNAseq and DNA Whole-Exome Sequence Analysis Reveal |
|
Abstract Number: 4558 |
|
Date: June 3, 2019 |
|
Time: 1:15 PM to 4:15 PM |
|
Location: Hall A |
|
Presenter: Greg Mayhew, PhD, Director, Bioinformatics, |
To read the abstract, please visit: http://abstracts.asco.org/239/AbstView_239_270173.html
About GeneCentric
GeneCentric Therapeutics is applying proprietary technology to identify
drug responder populations that enable development of precision medicine
drugs and improve patient outcomes. Our approach applies the Cancer
Subtype Platform (CSP®) to parse complex tumor biology into
genomic signatures revealing high-resolution cancer subtypes, with
potential as universal biomarkers for susceptibility to multiple classes
of agents including immune-based, molecularly targeted and
chemotherapeutics. We are commercializing our technology through
strategic collaborations with pharmaceutical and biotech companies to
define responder populations applicable throughout the drug development
cycle. In addition to bladder cancer, GeneCentric has developed gene
expression-based Cancer Profilers for lung, head and neck, and bladder
cancer. GeneCentric has established several pharmaceutical
collaborations, including an alliance with Bristol Myers Squibb in
immuno-oncology. For more information, please visit www.genecentric.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005281/en/